QuidelOrtho Corporation
NASDAQ:QDELMedical - Instruments & Supplies
+$0.09 today
- Market cap
- $656.62M
- Beta
- 0.76
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$17.76
Volume 2.13M
Average 2.35M
QDEL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
QuidelOrtho CorporationNASDAQ: QDEL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $112.9M rose 5.4% year over year, ahead of the +0.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Depreciation & amortization amounted to 16.2% of revenue in FY2025, down 0.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +5.4% holds above the trailing-twelve-month pace of +0.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 442M USD
- Year-over-year change
- -2.5%
- 4-year CAGR
- +68.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 442M | -2.5% |
| FY2024 | 2024-12-29 | 453.4M | -0.8% |
| FY2023 | 2023-12-31 | 457.2M | +61.2% |
| FY2022 | 2023-01-01 | 283.6M | +421.5% |
| FY2021 | 2021-12-31 | 54.38M | — |
Depreciation & Amortization vs competitors
How QDEL compares with its peers on the latest reported figures
- QDEL's LTM Mar 2026 depreciation & amortization of $447.8M is the 3rd largest of the 9 companies compared; the peer median is $108.97M.
- Its year-over-year change of +0.5% is the 4th highest of 8, against a peer median of -0.2%.
- Depreciation & amortization amounts to 16.9% of revenue for QDEL, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.11B | +11.2% | -6.3% | 6.6% | |
| LTM Sep 2026 | $585M | +4.5% | +9.3% | 4.9% | |
| LTM Mar 2026 | $447.8M | +0.5% | +15.9% | 16.9% | |
| LTM Jul 2026 | $412.24M | -0.2% | -1.7% | 14.2% | |
| LTM Jun 2026 | $127.6M | -23.5% | +6.4% | 4.9% | |
| LTM Mar 2026 | $90.34M | -5.7% | -5.5% | 15.5% | |
| LTM Mar 2026 | $9.86M | -9.2% | -91.3% | 8.7% | |
| LTM Dec 2025 | $2.69M | +44.1% | +4.8% | 6.1% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $0 | — | — | 0.0% |
| Peer median (excluding QDEL) | $108.97M | -0.2% | -1.7% | 6.3% | |
Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 704.23M | 548.7M | (10.1M) | (2.05B) | (1.13B) |
| Depreciation & Amortization | 54.38M | 283.6M | 457.2M | 453.4M | 442M |
| Deferred Income Tax | 24.67M | (44M) | (11.6M) | (99.3M) | 6.3M |
| Stock-Based Compensation | 25.4M | 48.4M | 51.6M | 42.1M | 45.9M |
| Change in Working Capital | (2.78M) | (53.2M) | (194.9M) | (158.7M) | (125.8M) |
| Accounts Receivables | 118.85M | 150.2M | 160M | 5.4M | (117.5M) |
| Inventory | (85.04M) | (116.9M) | (211.6M) | (134.1M) | (148.3M) |
| Accounts Payables | 10.45M | 23.5M | 3M | (23.4M) | 40M |
| Other Working Capital | (47.04M) | (110M) | (146.3M) | (6.6M) | 100M |
| Other Non-Cash Items | (34K) | 101.8M | (12M) | 1.9B | 868.6M |
| Operating Cash Flow | 805.87M | 885.3M | 280.2M | 83M | 105.2M |
| Capital Expenditures | (292.72M) | (140.9M) | (209.3M) | (195.1M) | (188.2M) |
| Acquisitions (Net) | 0 | (1.51B) | 0 | 0 | 6.5M |
| Purchases of Investments | (67.45M) | (63.7M) | (60.1M) | (7.2M) | 0 |
| Sales of Investments | 3.76M | 53.4M | 78.3M | 63.1M | 0 |
| Other Investing Activities | 36.88M | 18.4M | 3.5M | (10.7M) | (11M) |
| Investing Cash Flow | (319.53M) | (1.64B) | (187.6M) | (149.9M) | (192.7M) |
| Debt Repayment | (300K) | 346.2M | (226.4M) | 53.4M | 155.1M |
| Common Stock Issued | 7.6M | 26.4M | 11.6M | 5M | 6.1M |
| Common Stock Repurchased | (103.44M) | (74.3M) | (7.2M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (76.99M) | (46.3M) | (43.8M) | (9.6M) | (5.4M) |
| Financing Cash Flow | (173.18M) | 252M | (265.8M) | 48.8M | 155.8M |
| Effect of Forex Changes | (352K) | (2M) | (1.2M) | (2.9M) | 3M |
| Net Change in Cash | 312.81M | (508.9M) | (174.4M) | (21M) | 71.3M |
| Free Cash Flow | 513.15M | 744.4M | 70.9M | (112.1M) | (83M) |
QuidelOrtho Corporation
NASDAQ:QDEL
Intrinsic Alpha fair value
Locked
Current Price
$9.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.